Shares of Pulsenmore Ltd (Nasdaq: PLSM) experienced a significant surge in premarket trading on Wednesday, with volume reaching 19.19 million shares, far exceeding the stock's 65-day average of just 17,740 shares. The spike came after the company announced a strategic partnership with Ouma Health to integrate its FDA-authorized home ultrasound system into Ouma's virtual maternity care platform for the U.S. market.
The deal, announced on Wednesday, June 24, 2026, did not disclose financial terms or patient coverage targets. Pulsenmore cautioned that the outcomes are subject to significant risks, including manufacturing, sales, new market entry, partner performance, capital availability, regulatory changes, and geopolitical volatility in the Middle East.
Pulsenmore's stock closed at $3.41 on Tuesday. The premarket activity was notable as the Nasdaq regular trading session had not yet opened at the time of the announcement. The release was made while the Tel Aviv Stock Exchange (TASE) was still open, with trading hours from 9:59 a.m. to 5:14 p.m. local time.
Under the partnership, Ouma Health plans to incorporate Pulsenmore's home ultrasound device into its existing virtual maternity care offering, which leverages telehealth and connected devices to provide pregnancy care without relying solely on in-clinic visits. Ouma's services span from preconception through postpartum care.
Dr. Elazar Sonnenschein, founder and CEO of Pulsenmore, stated that the collaboration could extend ultrasound capabilities "beyond the walls of the clinic." Dr. Sina Haeri, CEO of Ouma Health, noted that the device could make virtual maternity care "more clinically complete." The companies are targeting patients in areas with limited access to in-person prenatal care, particularly those in what March of Dimes calls "maternity care deserts"—counties lacking a birthing hospital, birth center with obstetric care, or any obstetric provider. Over 35% of U.S. counties fall into this category.
Pulsenmore's ES device is listed in the FDA's De Novo database as an at-home ultrasound imaging device intended for lay users, with the decision recorded on October 31, 2025. The De Novo pathway is used for low- to moderate-risk devices without a predicate.
Ouma Health has been expanding its U.S. presence. On June 23, the company announced an extension of its maternal-fetal medicine partnership with MultiCare Health System, covering six outpatient sites and inpatient teleMFM services at Tacoma General Hospital. Maternal-fetal medicine addresses high-risk pregnancies.
Pulsenmore operates in a niche segment of the ultrasound market. GE HealthCare lists Pulsenmore alongside its Voluson women's health ultrasound line as a doctor-prescribed at-home product. Competitor Butterfly Network has its own FDA-cleared handheld ultrasound line and received FDA clearance in March for an AI tool that dates pregnancies.
Financially, Pulsenmore reported 2025 revenue of $12.5 million, a significant increase from approximately $2.6 million in 2024. However, $9.6 million of that revenue came from a one-time settlement with GE. The company's net loss narrowed to $5 million from $10 million in the prior year. Pulsenmore ended 2025 with $21.7 million in liquid assets.
Despite the positive market reaction, the lack of specific financial details in the Ouma agreement, including pricing, minimum volume commitments, and revenue timelines, has left investors with uncertainties. Pulsenmore emphasized that the expected results from the deal remain subject to various risks, highlighting the speculative nature of the partnership's near-term impact.
